Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML)
Indrasari, Yulia
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Platelet Aggregation Test on Different Dual Antiplatelet Strategies in Acute Coronary Syndrome Amalia, Yustisia; Hernaningsih, Yetti; Yusuf, Moch; Indrasari, Yulia
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 32 No. 1 (2025)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v32i1.2675

Abstract

Acute coronary syndrome (ACS) is frequently accompanied by platelet hyper-aggregation, which requires percutaneous coronary intervention (PCI) as definitive management, as it has the side effect of thrombosis, so platelet function must be monitored. This study aimed to evaluate platelet aggregation between the loading and maintenance doses of different DAPT combinations in patients with ACS undergoing PCI. This study employed a prospective cohort design with consecutive sampling, conducted at Dr. Soetomo General Academic Hospital in Surabaya and Universitas Airlangga Hospital in Indonesia. Patients with active bleeding, hemodynamic instability, or contraindications to antiplatelet agents were excluded. Patients were divided into a high-risk bleeding ACS group treated with aspirin–clopidogrel and a low-risk bleeding ACS group treated with aspirin–ticagrelor or aspirin–prasugrel according to the ARC-HBR score. Platelet aggregation tests (% maximum aggregation) were performed using the light transmission aggregometry method with adenosine diphosphate (ADP), collagen (COL), and epinephrine (EPI) agonists. Statistical analysis was performed to compare the differences between groups.The study included a total of 68 ACS patients with PCI: aspirin–clopidogrel (22.1%), aspirin–ticagrelor (44.1%), and aspirin–prasugrel (33.8%). There was no significant difference in platelet aggregation between groups with EPI and COL agonists. ADP agonists showed a significant difference between the loading and maintenance doses in the aspirin–ticagrelor and aspirin–prasugrel groups. The most important difference was observed in the aspirin–prasugrel group (95% CI: -22.68, -9.00; p = 0.000). Aspirin–prasugrel is the most potent inhibitor of platelet aggregation in patients with ACS undergoing PCI.
Co-Authors Amalia, Yustisia Yetti Hernaningsih Yusuf, Moch